Methods for modulating antigen-specific immune responses
AssigneeSchering Corporation
InventorsMaria-Grazia Roncarolo, Rene de Waal Malefyt, Rosa Bacchetta, Herve M. Groux, Jan E. de Vries
Life of this patent
Estimating the term…
Abstract
Interleukin-10 for producing a population of cells which are capable of inhibiting or suppressing reactions to alloantigens, for example in graft-versus-host disease or tissue rejection, is described. Interleukin-10 for reducing responses in mixed lymphocyte response (MLR) is also described. Exogenous or induced endogenous IL-10 may be used for the inhibition or suppression of the reactions to alloantigens.
Claims16
A method of inhibiting an antigen-specific response of a T cell to subsequent presentation of said antigen, comprising administering to said T cell an effective amount of exogenous interleukin-10 and said antigen in vitro.
A method of suppressing a T cell response to an antigen, comprising administering to said T cell in vitro a combination of:
- a) IL-10;
- and
- b) either said antigen or anti-CD3 antibodies.
A method of suppressing a subsequent response of a T cell to an antigen, comprising administering to a T cell in vitro a combination of:
- a) exogenous IL-10;
- and
- b) either antigen or anti-CD3 antibodies.
A method of inducing anergy to an MHC antigen in a T cell, comprising administering to a precursor of said T cell in vitro;
- a) exogenous IL-10 and said antigen;
- or
- b) exogenous IL-10 and an anti-CD3 antibody.
Dependencies are inferred from the claim text.